Category

Announcements

Exercise of Options

By Announcements
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will issued 25,147 ordinary shares of 1 penny each (“Option Shares”) in settlement of options that have been exercised by a former employee. The options were exercised at prices of US $0.20877 and $0.69589 per ordinary share for total consideration of US $8,750. Admission to trading on AIM (“Admission”) of the Option Shares, which will rank pari passu with the existing Ordinary Shares, has been applied for, and it is expected that Admission will become effective and dealings in the new Ordinary Shares will commence on 23 July 2015. Total Voting Rights Following Admission, the total issued share capital of...
Read More

Exercise of Options

By Announcements
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will issued 82,627 ordinary shares of 1 penny each (“Option Shares”)  in settlement of options that have been exercised by a former employee.  The options were exercised at a price of US $0.2088 per ordinary share for total consideration of US $17,252.52. Admission to trading on AIM (“Admission”) of the Option Shares, which will rank pari passu with the existing Ordinary Shares, has been applied for, and it is expected that Admission will become effective and dealings in the new Ordinary Shares will commence on 16 July 2015. Total Voting Rights Following Admission, the total issued share capital of the Company...
Read More

Result of General Meeting

By Announcements
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce that at the General Meeting held earlier today all resolutions as set out in the Notice of General Meeting annexed to the circular to shareholders dated 23 June 2015 were duly passed. The passing of the resolutions represents the satisfaction of the first of the two conditions to completion of the conditional placing of 44,000,000 ordinary shares announced by the Company on 23 June 2015. The second condition, being the successful grant of the QIDP designation for iclaprim in the US (such grant not to be later than 24 July 2015), remains to be satisfied. Enquiries Motif Bio plc Graham Lumsden, Chief Executive Officer Robert Bertoldi, Chief Financial Officer...
Read More

Motif Selected to Present at World’s Largest Biotech Event

By Announcements
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria, announced today that the Company has been selected to present at the 2015 BIO International Convention, the leading global event for the Biotechnology sector. BIO International is the world’s largest biotech meeting, regularly attracting 15,000 of the world’s most powerful biotechnology and pharmaceutical players from 65 countries, offering unparalleled business partnering, education and networking. The convention is to be held in the Pennsylvania Convention Centre, Philadelphia, Pennsylvania, USA, on 15-18 June 2015. Enquiries Motif Bio plc Graham Lumsden, Chief Executive Officer Robert Bertoldi, Chief Financial Officer info@motifbio.com Plumtree Capital Limited (Financial Adviser) Stephen...
Read More

Funding Strategy Update

By Announcements
The Board of Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today updated investors with its funding strategy following agreement on 14th April 2015 by the U.S. Food and Drug Administration (FDA) with the proposed Phase 3 clinical development programme for the Company's lead product candidate, iclaprim.  The Company anticipates commencing Phase 3 trials in the second half of this year. To fund these trials Motif is continuing to explore available options, including strategic partnerships with other pharmaceutical companies, non-dilutive government funding from grants, and market funding should the valuation of the Company be supportive. The Company is therefore pleased to announce that it has been selected to present at BioEquity Europe 2015. ...
Read More